Cargando…
Perimenstrual asthma: from pathophysiology to treatment strategies
The prevalence of asthma is about 9,7 % in women and 5,5 % in men. Asthma can deteriorate during the perimenstrual period, a phenomenon known as perimenstrual asthma (PMA), which represents a unique, highly symptomatic asthma phenotype. It is distinguished from traditional allergic asthma by aspirin...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967997/ https://www.ncbi.nlm.nih.gov/pubmed/27482380 http://dx.doi.org/10.1186/s40248-016-0065-0 |
_version_ | 1782445603116023808 |
---|---|
author | Graziottin, Alessandra Serafini, Audrey |
author_facet | Graziottin, Alessandra Serafini, Audrey |
author_sort | Graziottin, Alessandra |
collection | PubMed |
description | The prevalence of asthma is about 9,7 % in women and 5,5 % in men. Asthma can deteriorate during the perimenstrual period, a phenomenon known as perimenstrual asthma (PMA), which represents a unique, highly symptomatic asthma phenotype. It is distinguished from traditional allergic asthma by aspirin sensitivity, less atopy, and lower lung capacity. PMA incidence is reported to vary between 19 and 40 % of asthmatic women. The presence of PMA has been related to increases in asthma-related emergency department visits, hospitalizations and emergency treatment including intubations. It is hypothesized that hormonal status may influence asthma in women, focusing on the role of sex hormones, and specifically on the impact of estrogens’ fluctuations at ovulation and before periods. This paper will focus on the pathophysiology of hormone triggered cycle related inflammatory/allergic events and their relation with asthma. We reviewed the scientific literature on Pubmed database for studies on PMA. Key word were PMA, mastcells, estrogens, inflammation, oral contraception, hormonal replacement therapy (HRT), and hormone free interval (HFI). Special attention will be devoted to the possibility of reducing the perimenstrual worsening of asthma and associated symptoms by reducing estrogens fluctuations, with appropriate hormonal contraception and reduced HFI. This novel therapeutical approach will be finally discussed. |
format | Online Article Text |
id | pubmed-4967997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49679972016-08-02 Perimenstrual asthma: from pathophysiology to treatment strategies Graziottin, Alessandra Serafini, Audrey Multidiscip Respir Med Review The prevalence of asthma is about 9,7 % in women and 5,5 % in men. Asthma can deteriorate during the perimenstrual period, a phenomenon known as perimenstrual asthma (PMA), which represents a unique, highly symptomatic asthma phenotype. It is distinguished from traditional allergic asthma by aspirin sensitivity, less atopy, and lower lung capacity. PMA incidence is reported to vary between 19 and 40 % of asthmatic women. The presence of PMA has been related to increases in asthma-related emergency department visits, hospitalizations and emergency treatment including intubations. It is hypothesized that hormonal status may influence asthma in women, focusing on the role of sex hormones, and specifically on the impact of estrogens’ fluctuations at ovulation and before periods. This paper will focus on the pathophysiology of hormone triggered cycle related inflammatory/allergic events and their relation with asthma. We reviewed the scientific literature on Pubmed database for studies on PMA. Key word were PMA, mastcells, estrogens, inflammation, oral contraception, hormonal replacement therapy (HRT), and hormone free interval (HFI). Special attention will be devoted to the possibility of reducing the perimenstrual worsening of asthma and associated symptoms by reducing estrogens fluctuations, with appropriate hormonal contraception and reduced HFI. This novel therapeutical approach will be finally discussed. BioMed Central 2016-08-01 /pmc/articles/PMC4967997/ /pubmed/27482380 http://dx.doi.org/10.1186/s40248-016-0065-0 Text en © Graziottin and Serafini. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Graziottin, Alessandra Serafini, Audrey Perimenstrual asthma: from pathophysiology to treatment strategies |
title | Perimenstrual asthma: from pathophysiology to treatment strategies |
title_full | Perimenstrual asthma: from pathophysiology to treatment strategies |
title_fullStr | Perimenstrual asthma: from pathophysiology to treatment strategies |
title_full_unstemmed | Perimenstrual asthma: from pathophysiology to treatment strategies |
title_short | Perimenstrual asthma: from pathophysiology to treatment strategies |
title_sort | perimenstrual asthma: from pathophysiology to treatment strategies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967997/ https://www.ncbi.nlm.nih.gov/pubmed/27482380 http://dx.doi.org/10.1186/s40248-016-0065-0 |
work_keys_str_mv | AT graziottinalessandra perimenstrualasthmafrompathophysiologytotreatmentstrategies AT serafiniaudrey perimenstrualasthmafrompathophysiologytotreatmentstrategies |